Galena linked to Seeking Alpha stock promotion scheme, TheStreet says For the second time the investment website Seeking Alpha has been forced to take action against posters using multiple aliases to tout Galena and this most recent incident links Galena to a stock-promotions firm that published the articles as part of a broader campaign to boost Galena's stock price, according to TheStreet's Adam Feuerstein. Reference Link
Galena receives notice of allowance of U.S. patent for NeuVax Galena Biopharma announced the United States Patent Office issued a Notice of Allowance for an additional U.S. patent application covering multiple uses of NeuVax. NeuVax is a peptide immunotherapy currently being evaluated for the prevention of cancer recurrence and is Galena's lead development agent in multiple ongoing and planned clinical trials. This patent will expand both the protection and the potential population of cancer patients NeuVax may address. Once issued, the patent will expire in 2028, not including any patent term extensions.